Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
CytomX Therapeutics is a biotechnology business based in the US. CytomX Therapeutics stocks (CTMX.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $7.08 – a decrease of 3.45% over the previous week. CytomX Therapeutics employs 116 staff and has a trailing 12-month revenue of around $67.6 million.
National Bank Direct Brokerage
Finder Award
Interactive Brokers
| Latest market close | $1.68 |
|---|---|
| 52-week range | $1.17 - $3.02 |
| 50-day moving average | $1.69 |
| 200-day moving average | $1.78 |
| Wall St. target price | $2.52 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.96 |
Note: The dollar amounts in the table below are in Canadian dollars.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the close of $1.68 from 2023-06-01
| 1 week (2023-05-26) | -3.45% |
|---|---|
| 1 month (2023-05-02) | 1.82% |
| 3 months (2023-03-02) | -21.86% |
| 6 months (2022-12-02) | -1.75% |
| 1 year (2022-06-01) | 8.39% |
|---|---|
| 2 years (2021-05-29) | N/A |
| 3 years (2020-06-02) | 8.12 |
| 5 years (2018-06-01) | 25.53 |
| Revenue TTM | $67.6 million |
|---|---|
| Gross profit TTM | $53.2 million |
| Return on assets TTM | -15.81% |
| Return on equity TTM | -5475.03% |
| Profit margin | -104.47% |
| Book value | $-1.31 |
| Market capitalisation | $113.8 million |
TTM: trailing 12 months
We're not expecting CytomX Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, CytomX Therapeutics's shares have ranged in value from as little as $1.17 up to $3.02. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while CytomX Therapeutics's is 0.6527. This would suggest that CytomX Therapeutics's shares are less volatile than average (for this exchange).
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; CX-2051, a conditionally activated ADC that targets epithelial cell adhesion molecule-expressing epithelial cancers; and CX-801, a dually masked, conditionally activated version of Interferon alpha-2b therapy for a range of tumor types. The company also develops BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I/II clinical trials for the treatment of solid tumors; and CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. It has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc. , Bristol-Myers Squibb Company, Astellas Pharma Inc.
Your guide to how ETFs work and whether this type of investment is right for you.
Read more…
The best stock trading app for beginners is easy to use and offers free trades.
Read more…
Learning how to read stock charts and recognize chart patterns can unlock your success as a trader.
Read more…Compare some of the best bad credit loans in PEI.
Your guide to the features, interest rates and fees to expect when you apply for a short-term loan with Credito.
Pay for unexpected bills and avoid overdrafts when you sign up for apps like Bree.
Take a closer look at the debt relief solutions, features and fees of Debt Relief Canada.
Learn more about Desjardins Online Brokerage (Disnat) to see if it’s the right broker for you.
We show you the best prepaid credit cards in Canada, whether you’re looking for a prepaid card with no fees, cash back rewards, or travel perks, or more.
This guide provides step-by-step instructions on how to buy Sui, lists some exchanges where you can get it and provides daily price data on (SUI).
Compare apps like Nyble in Canada to access emergency funding.
Your guide to buying and financing a car in Canada with RightRide.
Your guide to bad credit car loans in BC and how to find the right financing for your needs.
